Page 56 - GPD-2-1

Gene & Protein in Disease

ORIGINAL RESEARCH ARTICLE
A novel signature identified by pyroptosis-related

lncRNAs clusters predicts prognosis and tumor
immune microenvironment for pediatric acute

myeloid leukemia

Jie Lu, Xinyu Chang, Guowei Zheng, Xiting Cao, Zhenwei Wang, Hao Zhu,
Shuaijie Gao, and Yuanlin Xi*

Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University,
Zhengzhou 450001, Henan, China

Abstract

Pyroptosis is a recently discovered programmed cell death that is involved in tumor
formation, prognosis, and curative effect. Pyroptosis-related long non-coding
ribonucleic acids (PR-lncRNAs) play key roles in tumorigenesis and tumor progression.
However, the inherent relationship between PR-lncRNAs and the prognosis of
pediatric acute myeloid leukemia (AML) remains unclear. For this reason, the
association of PR-lncRNAs with the prognosis and tumor microenvironment features
was analyzed using the Therapeutically Applicable Research to Generate Effective
Treatment (TARGET) database. We classified three clusters based on PR-lncRNAs
expressions and identified 841 differentially expressed PR-lncRNAs related to overall
survival time. Seven key lncRNAs were then identified by least absolute shrinkage
*Corresponding author:
Yuanlin Xi and selection operator (LASSO)-Cox and multivariate Cox. A signature based on
(xyl@zzu.edu.cn) these seven lncRNAs was also established, and the patients were separated into
Citation: Lu J, Chang X, Zheng G, two groups according to their risk score. The high-risk group was characterized by
et al., 2023, A novel signature poorer prognosis, lower expression of immune checkpoints, lower microsatellite
identified by pyroptosis-related instability or microsatellite stability (MSI-L/MSS), and lower drug sensitivity. The
lncRNAs clusters predicts
prognosis and tumor immune results demonstrated that PR-lncRNAs have a potential effect on the tumor immune
microenvironment for pediatric microenvironment, clinicopathological features, and prognosis in pediatric AML. The
acute myeloid leukemia. Gene nomogram and decision curve analysis suggested that the risk score is one of the
Protein Dis, 2(1):230.
https://doi.org/10.36922/gpd.v2i1.230 most accurate of any other and provided a basis for the exploration of the immune
microenvironment of the cell pyroptosis-associated subtypes in children with AML
Received: October 19, 2022 and the construction of a prognostic model with seven key PR-lncRNAs, which
Accepted: November 22, 2022
Published Online: December 28, 2022 provides an approach to evaluate the prognosis of pediatric AML patients.
Copyright: © 2022 Author(s).
This is an Open Access article Keywords: Pediatric acute myeloid leukemia; Pyroptosis; Long non-coding RNAs;
distributed under the terms of the
Creative Commons Attribution Prognostic signature; Tumor immune microenvironment
License, permitting distribution,
and reproduction in any medium,
provided the original work is
properly cited. 1. Introduction
Publisher’s Note: AccScience
Publishing remains neutral with Acute myeloid leukemia (AML) is a hematologic malignancy with morphological,
regard to jurisdictional claims in
published maps and institutional immunophenotypic, germline, and somatic cytogenetic and genetic abnormalities.
affiliations. Pediatric AML is the second most common form of leukemia in children, with a mortality

Volume 2 Issue 1 (2023) 1 https://doi.org/10.36922/gpd.v2i1.230